Compare Docusign Inc (DOCU) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Docusign Inc trades at $71.08 (market cap $13.35B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: Docusign Inc is far larger — about 2.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 3,158,858). Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DOCU | IOVA | |
|---|---|---|
Market Cap | $13.35B | $6.04B |
Volume | 3,158,858 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $73.14 | $14.82 |
52-Week Low | $41.75 | $1.81 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $12.76B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 3.67% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. The stock is supported by AI-driven IAM adoption and leadership in signing workflow software, as noted in recent news.
Outlook is mixed: growth from AI and market position offers upside, but high valuation (P/E 43.55), insider selling, and slowing revenue growth pose risks. Analyst consensus is cautious with a $68.75 target below current price, suggesting limited near-term gains amid competitive and execution challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
